BamSEC and AlphaSense Join Forces
Learn More

Palvella Therapeutics Inc.

NASDAQ: PVLA    
Share price (1/8/25): $14.25    
Market cap (1/8/25): $18.8 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.30
from 8-K 4 pages Palvella Therapeutics, Inc. 2024 Equity Incentive Plan Notice of Grant of Restricted Stock Units Award
12/34/56
EX-10.29
from 8-K 6 pages Palvella Therapeutics, Inc. 2024 Equity Incentive Plan Stock Option Grant Notice and Stock Option Agreement
12/34/56
EX-10.27
from 8-K 30 pages Form of Contingent Value Rights Agreement by and Among Pieris Pharmaceuticals, Inc., Shareholder Representative Services LLC, as the Holder Representative, and Computershare Inc. and Computershare Trust Company, N.A., Acting Jointly as Rights Agent Dated as of December 13, 2024 1
12/34/56
EX-10.26
from 8-K 25 pages Registration Rights Agreement
12/34/56
EX-10.24
from 8-K 6 pages Palvella Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.23
from 8-K 11 pages Thomas Bures *** *** Re: Separation Agreement Dear Tom
12/34/56
EX-10.22
from 8-K 10 pages Stephen Yoder *** *** Re: Separation Agreement Dear Steve
12/34/56
EX-10.1
from 8-K 15 pages Palvella Therapeutics, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.1
from 425 15 pages Palvella Therapeutics, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 10 pages Certain Identified Information Has Been Excluded From This Exhibit in Accordance With Regulation S-K Item 601(a)(6) Because It Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.28
from S-4/A 8 pages Severance Agreement
12/34/56
EX-10.27
from S-4/A 3 pages Certain Identified Information Has Been Excluded From This Exhibit in Accordance With Regulation S-K Item 601(a)(6) Because It Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.19
from S-4/A 3 pages First Amendment to Development Funding and Royalties Agreement
12/34/56
EX-10.2
from 10-Q 1 page Material contract
12/34/56
EX-10.1
from 10-Q 7 pages Amended and Restated Articles of Incorporation of Pieris Pharmaceuticals, Inc
12/34/56
EX-10.26
from S-4 2 pages Certain Identified Information Has Been Excluded From This Exhibit in Accordance With Regulation S-K Item 601(a)(6) Because It Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.25
from S-4 2 pages Certain Identified Information Has Been Excluded From This Exhibit in Accordance With Regulation S-K Item 601(a)(6) Because It Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. [***] Indicates That Information Has Been Redacted
12/34/56
EX-10.24
from S-4 7 pages Severance Agreement
12/34/56
EX-10.23
from S-4 7 pages Severance Agreement
12/34/56
EX-10.22
from S-4 2 pages Certain Identified Information Has Been Excluded From This Exhibit in Accordance With Regulation S-K Item 601(a)(6) Because It Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. [***] Indicates That Information Has Been Redacted
12/34/56